Skip to content
Assyro AI
FDA Purple Book product · Interchangeable

Selarsdi

ustekinumab-aekn

Selarsdi, BLA 761343, is listed in the FDA Purple Book as a 351(k) interchangeable biosimilar. This page consolidates 4 exact FDA presentation rows, and FDA names Stelara as its reference product. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.

351(k) InterchangeableBLA 761343 4 presentationsRxLicensed Alvotech USA Inc.
Approved
Apr 16, 2024
License type
351(k) Interchangeable
Marketing
Rx
Listed patents
12
Selarsdi (ustekinumab-aekn) is a Interchangeable referencing ustekinumab, licensed under a 351(k) BLA in 2024; the Purple Book lists Alvotech USA Inc. as the BLA applicant, not necessarily the manufacturer or commercial supplier. Its interchangeable biosimilar designation may permit pharmacy-level substitution for the reference product without prescriber intervention, subject to state law; it is not a superiority claim. The Purple Book lists 12 published patents for this product.

Sourced from the FDA Purple Book · verified Oct 08, 2026

What this Purple Book record establishes

Regulatory interpretation
Ask AI

BLA number

761343

Regulatory role

351(k) interchangeable biosimilar

Applicant

Alvotech USA Inc.

Applicant is not automatically the physical manufacturer.

Presentations

4

Exact FDA presentation rows under this BLA.

Approval

Apr 16, 2024

Reference product

Stelara

Selarsdi is an FDA-designated interchangeable biosimilar.

Selarsdi is a 351(k) biosimilar of Stelara and carries an interchangeability designation.

Substitution boundary

An interchangeable designation may permit pharmacy-level substitution for the reference product without prescriber intervention, depending on state pharmacy law; it is not a claim of clinical superiority.

Key dates

Licensure & exclusivity
Ask AI
  1. Approval

    Approval date of this BLA submission.

    Apr 16, 2024

    2 yr 8 mo ago

  2. Today

Strengths & presentations

4 FDA presentation rows · BLA 761343
Ask AI

Strength

45MG/0.5ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

2225

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Exact presentation matrix

One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.

Exact FDA Purple Book presentation rows for this BLA
ProductStrengthDosage formRoutePresentationLicensureMarketing
00145MG/0.5MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
00290MG/MLInjectionSubcutaneousPre-Filled SyringeLicensedRx
003130MG/26ML (5MG/ML)InjectionIntravenousSingle-Dose VialLicensedRx
00445MG/0.5MLInjectionSubcutaneousSingle-Dose VialLicensedRx

Exact-source evidence coverage

Labeling & approval review

Current product label

Candidate awaiting exact-BLA match

FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.

Inspect FDA label candidate

FDA approval evidence

Exact-source research required

No independently matched exact-BLA FDA approval letter or review package is stored, so product-specific biosimilarity or switching evidence is not summarized.

Human review pending

Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 2 exact-source tasks. Labeling and approval-review claims stay unavailable until their own match gate passes.

Reference product family

Biosimilars & interchangeables

Selarsdi names Stelara as its reference product. The comparison below shows locally matched BLA candidates and follow-ons; it does not invent a reference BLA number when FDA did not state one in the loaded row.

Biosimilar of Stelara

Reference-family comparison

Purple Book comparison of products in this reference family
ProductDesignationBLAApprovedPresentationMarketing
Stelaraustekinumab351(a) ambiguous reference candidate125261Sep 25, 200945MG/0.5ML · SubcutaneousRx
Stelaraustekinumab351(a) ambiguous reference candidate761044Sep 23, 2016130MG/26ML (5MG/ML) · IntravenousRx
Selarsdiustekinumab-aekn351(k) interchangeable biosimilar761343Apr 16, 202445MG/0.5ML · SubcutaneousRx

Published patents

BPCIA patent list
Ask AI
Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
6,902,734Sep 25, 20233 yr 2 mo agoFDA
6,902,734Sep 25, 20233 yr 2 mo agoFDA
8,852,889Jul 06, 2032in 5 yr 8 moFDA
8,852,889Jul 06, 2032in 5 yr 8 moFDA
9,475,858Jul 06, 2032in 5 yr 8 moFDA
9,475,858Jul 06, 2032in 5 yr 8 moFDA
9,217,168Mar 14, 2033in 6 yr 5 moFDA
9,217,168Mar 14, 2033in 6 yr 5 moFDA
9,663,810Mar 14, 2033in 6 yr 5 moFDA
9,663,810Mar 14, 2033in 6 yr 5 moFDA
10,961,307Sep 24, 2039in 13 yrFDA
10,961,307Sep 24, 2039in 13 yrFDA

Practical characteristics and limits

Source-bounded interpretation

Presentation coverage

4 exact FDA presentation rows are consolidated under this BLA rather than split across duplicate pages.

Administration fields

The loaded rows list Subcutaneous and Intravenous and Injection; these are regulatory presentation fields, not dosing instructions.

Applicant boundary

Alvotech USA Inc. is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.

Regulatory comparison

Selarsdi is an FDA-designated interchangeable biosimilar. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.

Source provenance

FDA Purple Book data
Source kind · Monthly download
Checked Oct 08, 2026
FDA release · September 2026
  • advanced-searchAdvanced Search · Oct 08, 2026
  • monthly-downloadMonthly download · Oct 08, 2026
  • monthly-downloadMonthly download · Sep 21, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

What this record does not establish

  • Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
  • The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
  • Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
  • A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
  • Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.

Change history

Record versions
  • v8Oct 08, 2026
  • v7Oct 08, 2026
  • v6Sep 21, 2026
  • v5Aug 11, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Selarsdi: frequently asked questions

Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.

Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Selarsdi

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo